Compare JPMorgan Chase & Co (JPM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Medpace Holdings Inc — how do they compare? JPMorgan Chase & Co trades at $333.34 (market cap $880.98B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: JPMorgan Chase & Co is far larger — about 52.4× Medpace Holdings Inc's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Medpace Holdings Inc for 14 Days on average.
| JPM | MEDP | |
|---|---|---|
Market Cap | $880.98B | $16.82B |
Volume | 7,721,661 | 223,093 |
Sector | Financials | Health |
52-Week High | $365.18 | $630.19 |
52-Week Low | $282.84 | $393.42 |
Typical Hold Time | 127 Days | 14 Days |
Enterprise Value | $1.82T | $16.44B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $332.99, up 1.03% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to a projected $194.9B in 2026. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target. News highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
Outlook: JPM offers value with solid profitability and analyst upside, but risks include geopolitical tensions and cybersecurity threats. The stock's bearish technicals near support at $327 suggest caution, though institutional buying and high ROE provide stability. Investors should weigh strong fundamentals against macroeconomic headwinds highlighted in recent news.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
